STAGE III ANAL CANCER AJCC V8
Clinical trials for STAGE III ANAL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III ANAL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III ANAL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy plus chemo shows promise in advanced anal cancer trial
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy works better than chemotherapy alone for people with anal cancer that has spread or cannot be removed. About 205 adults with this type of cancer will take part. The goal is to see if the com…
Matched conditions: STAGE III ANAL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope: tailored therapy fights anal cancer in HIV patients
Disease control OngoingThis study tests a personalized approach for people with HIV who have anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab to help prevent the cancer from coming back. The goal is to see if …
Matched conditions: STAGE III ANAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Immunotherapy after Chemo-Radiation may keep anal cancer at bay
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab after standard chemoradiation can prevent anal cancer from coming back in patients with high-risk stage II-IIIB disease. About 344 adults with squamous cell carcinoma of the anus are enrolled. The main goal is to se…
Matched conditions: STAGE III ANAL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:58 UTC